€24.29
0.49%
L&S, Jun 28, 10:54 pm CET
ISIN
JP3463000004
Symbol
4502
Index
Sector
Industry

Takeda Pharmaceutical Share price

JPY4,172.00
+21.00 0.51% 1M
+125.00 3.09% 6M
+118.00 2.91% YTD
-382.00 8.39% 1Y
+426.00 11.37% 3Y
+349.00 9.13% 5Y
-527.00 11.22% 10Y
Tokyo, Closing price Fri, Jun 28 2024
ISIN
JP3463000004
Symbol
4502
Index
Sector
Industry

Key figures

Market capitalization JPY6.55t
Enterprise Value JPY11.55t
PER (TTM) P/E ratio 45.21
EV/FCF (TTM) EV/FCF 24.85
EV/Sales (TTM) EV/Sales 2.71
P/S ratio (TTM) P/S ratio 1.54
P/B ratio (TTM) P/B ratio 0.90
Dividend yield 4.70%
Last dividend (FY25) JPY196.00
Sales growth (TTM) Sales growth 5.87%
Turnover (TTM) Turnover JPY4.26t
EBIT (operating result TTM) EBIT JPY414.86b
Free cash flow (TTM) Free cash flow JPY464.90b
Cash position JPY457.80b
EPS (TTM) EPS JPY92.29
P/E ratio expected 73.26
P/S ratio expected 1.51
EV/Sales expected 2.67
Show more

Is Takeda Pharmaceutical a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Takeda Pharmaceutical Share analysis

Unlock scores for free

Analyst opinions

16 Analysts have issued a Takeda Pharmaceutical forecast:

8x Buy
50%
8x Hold
50%

Analyst opinions

16 Analysts have issued a Takeda Pharmaceutical forecast:

Buy
50%
Hold
50%

Financial data from Takeda Pharmaceutical

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
4,263,762 4,263,762
6% 6%
100%
- Direct costs 2,063,953 2,063,953
16% 16%
48%
2,199,809 2,199,809
2% 2%
52%
- Selling and administrative expenses 269,481 269,481
19% 19%
6%
- Research and development costs 729,924 729,924
15% 15%
17%
1,200,404 1,200,404
6% 6%
28%
- Depreciation and amortization 785,548 785,548
18% 18%
18%
EBIT (operating result) EBIT 414,856 414,856
32% 32%
10%
Net profit 144,067 144,067
55% 55%
3%

Figures in millions JPY.

Don't miss a thing! We will send you all news about the Takeda Pharmaceutical share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Takeda Pharmaceutical Share News

marktEINBLICKE
more than 2 years ago
Evotec erweitert die Neurologie-Kooperation mit dem US-Pharmaunternehmen Bristol Myers Squibb. Der Deal bringt großes Potenzial.
marktEINBLICKE
almost 3 years ago
Evotec bleibt weiter auf dem Wachstumskurs, wie die neuesten Geschäftszahlen zeigen. Auch der starke Ausblick könnte die Aktie jetzt zu einer Top-Empfehlung aus dem MDAX machen.
marktEINBLICKE
about 3 years ago
Das Biotech-Unternehmen Evotec hat wieder einmal eine neue Kooperation an Land gezogen. An der Börse könnte Evotec deshalb in Kürze einen Meilenstein setzen.
More Takeda Pharmaceutical News

Company profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office Japan
CEO Christophe Weber
Employees 49,281
Founded 1781
Website www.takeda.co.jp

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now